Joaquin Duato, J&J CEO (David Zorrakino/Europa Press via Getty Images)

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

John­son & John­son laid out their pipeline and medtech strate­gies Tues­day, promis­ing 20 new drugs that can help grow sales 5% to 7% a year through 2030, start­ing with $57 bil­lion in 2025. R&D chief John Reed, in an ear­li­er in­ter­view with End­points News, said their three pil­lars of fo­cus would be on­col­o­gy, im­munol­o­gy and neu­ro­science.

Through­out the pre­sen­ta­tion, ex­ecs laid out the specifics of how they planned to get to their high tar­get. Here are a few of the more no­table things to come out of the af­ter­noon:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.